ArticleBMC veterinary research2026
Nodular conjunctivitis as a novel ocular manifestation of canine sterile granuloma/pyogranuloma syndrome.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSterile granuloma/pyogranuloma syndrome (SGPS) is an immune-mediated disease producing nodular and plaque-like skin lesions in dogs. Ocular involvement has been reported mainly in periocular skin and eyelids, with no histologically documented conjunctival lesions. This report describes a palpebral conjunctival nodule in a dog with SGPS and its distinction from nodular ocular surface diseases such as nodular granulomatous episcleritis and other differential diagnoses. CASE PRESENTATION: A 3-year-10-month-old Polish Tatra Dog presented with mucopurulent discharge, hyperaemia of the bulbar, palpebral, and third-eyelid conjunctivae, a firm 1 cm nodule on the right lower palpebral conjunctiva, and medial eyelid thickening with ectropion. Three months earlier, multiple cutaneous nodules had been diagnosed as SGPS. Topical and systemic corticosteroid therapy improved the skin lesions but neither the conjunctival mass nor the eyelid thickening, necessitating surgical excision of the nodule. In contrast, the eyelid thickening resolved during a subsequent prednisone taper, and no recurrence was observed over 20 months. Histopathology revealed a well-demarcated conjunctival stromal nodule with deep extension into the palpebral stroma, surrounding blood vessels, peripheral nerves, and the orbicularis oculi muscle. The infiltrate consisted of CD3⁺ T cells, CD20⁺/CD79⁺ B cells, plasma cells, MAC387-positive macrophages, and scattered Iba1-positive histiocytes, with small neutrophilic foci and no epithelioid cells, multinucleated giant cells, mitotic figures, or foreign material.
conclusionThis case represents the first histopathologically confirmed conjunctival manifestation of SGPS. Its conjunctival origin and mixed lymphocytic-histiocytic profile expand the recognized spectrum of SGPS and support including SGPS in the differential diagnosis for well-circumscribed conjunctival nodules. Surgical excision may be required when such lesions do not regress or cause mechanical dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.